Harrow, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
HROW Nasdaq 2834 www.harrow.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Harrow, Inc.

Are Options Traders Betting on a Big Move in Harrow Stock? - Jul 2nd, 2025 7:00 am
We Might See A Profit From Harrow, Inc. (NASDAQ:HROW) Soon - Jun 26th, 2025 11:58 am
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Jun 18th, 2025 5:00 am
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - Jun 9th, 2025 5:00 am
Insiders Favor Harrow And 2 Other Leading Growth Companies - May 30th, 2025 11:35 am
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - May 14th, 2025 8:07 am
Harrow to Present at Two Investor Conferences in May - May 14th, 2025 5:00 am
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - May 10th, 2025 1:03 am
Harrow Announces First-Quarter 2025 Financial Results - May 8th, 2025 2:01 pm
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - May 5th, 2025 5:00 am
3 Growth Stocks Insiders Are Betting On - Apr 28th, 2025 11:35 am
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - Apr 24th, 2025 8:00 am
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Apr 21st, 2025 2:26 pm
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Apr 10th, 2025 5:00 am
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Mar 29th, 2025 1:01 pm
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Mar 27th, 2025 2:01 pm
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Mar 27th, 2025 8:45 am
Harrow And 2 Insider Picks For Growth Potential - Mar 27th, 2025 5:05 am
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Mar 24th, 2025 5:00 am
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Mar 17th, 2025 2:01 pm